Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX).
David Cunningham
Research Funding - AstraZeneca; Merck KGaA; Roche
Istvan Lang
No relevant relationships to disclose
Vito Lorusso
No relevant relationships to disclose
Janja Ocvirk
Honoraria - Roche
Dongbok Shin
No relevant relationships to disclose
Derek J. Jonker
No relevant relationships to disclose
Stuart Osborne
Employment or Leadership Position - Roche
Niko Alexander Andre
Employment or Leadership Position - Roche
Stock Ownership - Roche
Daniel Waterkamp
Employment or Leadership Position - Roche
Stock Ownership - Roche
Mark P. Saunders
No relevant relationships to disclose